Prakash Manoharan
Overview
Explore the profile of Prakash Manoharan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, et al.
Endocr Relat Cancer
. 2021 Jun;
28(8):549-561.
PMID: 34061764
There is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We aimed to describe the treatments received in patients with advanced G3 NETs and compare their efficacy. Patients...
12.
Garcia-Torralba E, Spada F, Lim K, Jacobs T, Barriuso J, Mansoor W, et al.
Cancer Treat Rev
. 2021 Mar;
94:102168.
PMID: 33730627
Objective: This systematic review and meta-analysis aimed to develop an evidence-based summary of current knowledge of bone metastases (BMs) in neuroendocrine neoplasms (NENs), inform diagnosis and treatment and standardise management...
13.
Vickers A, Thiruthaneeswaran N, Coyle C, Manoharan P, Wylie J, Kershaw L, et al.
BJR Open
. 2020 Nov;
1(1):20180022.
PMID: 33178916
Objective: Soft tissue sarcomas (STS) are a rare, heterogeneous tumour group. Radiotherapy improves local control. CT is used to plan radiotherapy, but has poor soft tissue definition. MRI has superior...
14.
Megdanova-Chipeva V, Lamarca A, Backen A, McNamara M, Barriuso J, Sergieva S, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32708210
Pancreatic neuroendocrine tumours (PanNETs) are rare diseases and a good example of how research is not only feasible, but also of crucial importance in the scenario of rare tumours. Many...
15.
Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan P, Julyan P, et al.
ESMO Open
. 2020 Mar;
5(2).
PMID: 32188715
Background: Ga-DOTA0-Tyr3-octreotide (Ga-DOTATOC) positron emission tomography-CT (PET-CT) has superior diagnostic performance compared to the licensed tracer OctreoScan single photon emission CT-CT in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). A new...
16.
Lamarca A, Clouston H, Barriuso J, McNamara M, Frizziero M, Mansoor W, et al.
J Clin Med
. 2019 Oct;
8(10).
PMID: 31590343
The incidence of neuroendocrine neoplasms (NENs) is increasing, especially for patients with early stages and grade 1 tumours. Current evidence also shows increased prevalence, probably reflecting earlier stage diagnosis and...
17.
Lamarca A, Barriuso J, McNamara M, Hubner R, Manoharan P, Mansoor W, et al.
Neuroendocrinology
. 2019 Sep;
110(1-2):155-157.
PMID: 31527383
No abstract available.
18.
Manoharan P, Salem A, Mistry H, Faivre-Finn C
J Natl Compr Canc Netw
. 2019 Aug;
17(8):xxxixb.
PMID: 31390592
No abstract available.
19.
Lamarca A, Ross P, Wasan H, Hubner R, McNamara M, Lopes A, et al.
J Natl Cancer Inst
. 2019 May;
112(2):200-210.
PMID: 31077311
Background: The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing. The aim of the study was to provide reference survival data for patients with advanced iCCA treated with first-line cisplatin-gemcitabine chemotherapy...
20.
Manoharan P, Salem A, Mistry H, Gornall M, Harden S, Julyan P, et al.
J Thorac Oncol
. 2019 Apr;
14(7):1296-1305.
PMID: 31002954
Introduction: We used phase-3 CONVERT trial data to investigate the impact of fludeoxyglucose F 18 (F-FDG) positron emission tomography (PET)/computed tomography (CT) in SCLC. Methods: CONVERT randomized patients with limited-stage...